3.80
+0.1(+2.70%)
Currency In USD
| Previous Close | 3.7 |
| Open | 3.7 |
| Day High | 3.92 |
| Day Low | 3.65 |
| 52-Week High | 6.6 |
| 52-Week Low | 1 |
| Volume | 188,413 |
| Average Volume | 316,098 |
| Market Cap | 36.32M |
| PE | -2.44 |
| EPS | -1.56 |
| Moving Average 50 Days | 2.96 |
| Moving Average 200 Days | 2.16 |
| Change | 0.1 |
If you invested $1000 in SAB Biotherapeutics, Inc. (SABS) since IPO date, it would be worth $37.44 as of December 04, 2025 at a share price of $3.8. Whereas If you bought $1000 worth of SAB Biotherapeutics, Inc. (SABS) shares 3 years ago, it would be worth $355.14 as of December 04, 2025 at a share price of $3.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
GlobeNewswire Inc.
Nov 13, 2025 10:00 PM GMT
Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patientsMultiple SAFEGUARD trial sites activated; on-track to dose first patient by year-endRecent data presented at EASD and IPSAD provide further vali
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today annou
SAB BIO Highlights Data in Multiple Presentations at EASD
GlobeNewswire Inc.
Sep 19, 2025 11:24 AM GMT
-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study- -Data in multiple SAB presentations and